Vaccine Momentum: Social media chatter highlights Merck's recent Phase 3 success with Moderna on a personalized mRNA cancer vaccine, sparking optimism about pipeline innovation. Observers note the potential to reshape oncology approaches amid broader industry shifts.
Trial Setbacks: Discussions also focus on Merck halting two Phase 3 cancer studies, raising questions about near-term oncology catalysts. Some voices point to congressional trades and insider activity as signals of ongoing interest despite the news.
Pipeline Outlook: Analysts and traders debate Merck's strategy to expand its portfolio ahead of Keytruda's patent expiration, with calls for potential acquisitions to sustain growth. Overall tone reflects measured interest in long-term resilience.
Note: This discussion summary was generated from an AI condensation of post data.
Merck Insider Trading Activity
Merck insiders have traded $MRK stock on the open market 17 times in the past 6 months. Of those trades, 0 have been purchases and 17 have been sales.
Here’s a breakdown of recent trading of $MRK stock by insiders over the last 6 months:
- JENNIFER ZACHARY (EVP, General Counsel) sold 80,315 shares for an estimated $10,718,494
- DAVID MICHAEL WILLIAMS (EVP,Chief Info&Digital Officer) has made 0 purchases and 3 sales selling 52,847 shares for an estimated $6,805,145.
- RICHARD R. DELUCA (EVP&Pres, Merck Animal Heallth) has made 0 purchases and 8 sales selling 51,370 shares for an estimated $6,731,142.
- CHIRFI GUINDO (EVP, Access, Policy & Comms) has made 0 purchases and 2 sales selling 25,000 shares for an estimated $3,315,000.
- DAVID R. MARALDO (EVP & Pres. MMD) has made 0 purchases and 3 sales selling 18,706 shares for an estimated $2,407,797.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Merck Revenue
Merck had revenues of $16.6B in Q2 2026. This is an increase of 5.07% from the same period in the prior year.
You can track MRK financials on Quiver Quantitative's MRK stock page.
You can access data on MRK stock through the Quiver Quantitative API.
Merck Congressional Stock Trading
Members of Congress have traded $MRK stock 3 times in the past 6 months. Of those trades, 2 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $MRK stock by members of Congress over the last 6 months:
- REPRESENTATIVE MARIA ELVIRA SALAZAR has traded it 2 times. They made 2 purchases worth up to $100,000 on 08/19 and 0 sales.
- SENATOR ALAN ARMSTRONG sold up to $50,000 on 03/27.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
Merck Hedge Fund Activity
We have seen 1,804 institutional investors add shares of Merck stock to their portfolio, and 1,745 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 54,365,289 shares (+inf%) to their portfolio in Q2 2026, for an estimated $6,985,939,636
- JPMORGAN CHASE & CO added 43,886,420 shares (+inf%) to their portfolio in Q2 2026, for an estimated $5,639,404,970
- CAPITAL INTERNATIONAL INVESTORS added 14,516,428 shares (+1668.1%) to their portfolio in Q2 2026, for an estimated $1,865,360,998
- FISHER ASSET MANAGEMENT, LLC added 12,079,979 shares (+45.7%) to their portfolio in Q2 2026, for an estimated $1,552,277,301
- NORDEA INVESTMENT MANAGEMENT AB removed 5,024,243 shares (-58.9%) from their portfolio in Q2 2026, for an estimated $645,615,225
- CHARLES SCHWAB INVESTMENT MANAGEMENT INC added 4,600,064 shares (+9.2%) to their portfolio in Q2 2026, for an estimated $591,108,224
- PRICE T ROWE ASSOCIATES INC /MD/ removed 4,524,046 shares (-19.6%) from their portfolio in Q2 2026, for an estimated $581,339,911
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Merck Government Contracts
We have seen $1,949,629 of award payments to $MRK over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- E14 IMPERIAL PONDS PIT SCANNER ARRAY: $127,600
- EMERGENCY WINREVAIR: $105,209
- FISH MONITORING EQUIPMENT: $90,954
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.
Merck Price Targets
Multiple analysts have issued price targets for $MRK recently. We have seen 10 analysts offer price targets for $MRK in the last 6 months, with a median target of $139.5.
Here are some recent targets:
- Terence Flynn from Morgan Stanley set a target price of $113.0 on 07/09/2026
- Mohit Bansal from Wells Fargo set a target price of $150.0 on 07/08/2026
- Trung Huynh from RBC Capital set a target price of $142.0 on 07/08/2026
- Carter Gould from Cantor Fitzgerald set a target price of $120.0 on 07/06/2026
- Louise Chen from Scotiabank set a target price of $155.0 on 06/30/2026
- Tim Anderson from B of A Securities set a target price of $141.0 on 06/30/2026
- An analyst from CICC set a target price of $138.0 on 06/24/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
